Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.06
AIQ's Cash to Debt is ranked lower than
98% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.71 vs. AIQ: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
AIQ' s 10-Year Cash to Debt Range
Min: 0.01  Med: 0.07 Max: N/A
Current: 0.06
Equity to Asset -0.30
AIQ's Equity to Asset is ranked lower than
96% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. AIQ: -0.30 )
Ranked among companies with meaningful Equity to Asset only.
AIQ' s 10-Year Equity to Asset Range
Min: -0.39  Med: -0.08 Max: 0.04
Current: -0.3
-0.39
0.04
Interest Coverage 2.07
AIQ's Interest Coverage is ranked lower than
92% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10000.00 vs. AIQ: 2.07 )
Ranked among companies with meaningful Interest Coverage only.
AIQ' s 10-Year Interest Coverage Range
Min: 0.27  Med: 1.67 Max: 9999.99
Current: 2.07
0.27
9999.99
F-Score: 6
Z-Score: 0.84
M-Score: -3.09
WACC vs ROIC
4.34%
12.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.67
AIQ's Operating margin (%) is ranked higher than
79% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. AIQ: 11.67 )
Ranked among companies with meaningful Operating margin (%) only.
AIQ' s 10-Year Operating margin (%) Range
Min: -39.88  Med: 11.74 Max: 26.28
Current: 11.67
-39.88
26.28
Net-margin (%) 2.37
AIQ's Net-margin (%) is ranked higher than
58% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. AIQ: 2.37 )
Ranked among companies with meaningful Net-margin (%) only.
AIQ' s 10-Year Net-margin (%) Range
Min: -32.43  Med: 0.10 Max: 18.69
Current: 2.37
-32.43
18.69
ROA (%) 2.12
AIQ's ROA (%) is ranked higher than
60% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. AIQ: 2.12 )
Ranked among companies with meaningful ROA (%) only.
AIQ' s 10-Year ROA (%) Range
Min: -21.65  Med: -0.02 Max: 5.34
Current: 2.12
-21.65
5.34
ROC (Joel Greenblatt) (%) 27.58
AIQ's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.66 vs. AIQ: 27.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AIQ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -47.29  Med: 18.57 Max: 29.76
Current: 27.58
-47.29
29.76
Revenue Growth (3Y)(%) -4.70
AIQ's Revenue Growth (3Y)(%) is ranked lower than
71% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.20 vs. AIQ: -4.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AIQ' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.7  Med: 1.30 Max: 27
Current: -4.7
-4.7
27
» AIQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AIQ Guru Trades in Q2 2014

Jim Simons 603,260 sh (New)
Jim Simons 566,160 sh (+13.42%)
Howard Marks 4,756,491 sh (unchged)
» More
Q3 2014

AIQ Guru Trades in Q3 2014

Jim Simons 592,260 sh (+4.61%)
Howard Marks 4,756,491 sh (unchged)
» More
Q4 2014

AIQ Guru Trades in Q4 2014

Jim Simons 603,260 sh (+1.86%)
Howard Marks 4,756,491 sh (unchged)
» More
Q1 2015

AIQ Guru Trades in Q1 2015

Jim Simons 611,482 sh (+1.36%)
Howard Marks 4,756,491 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AIQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.93
AIQ's P/E(ttm) is ranked higher than
81% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. AIQ: 18.93 )
Ranked among companies with meaningful P/E(ttm) only.
AIQ' s 10-Year P/E(ttm) Range
Min: 10.21  Med: 23.60 Max: 868.06
Current: 18.93
10.21
868.06
Forward P/E 13.59
AIQ's Forward P/E is ranked higher than
83% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.16 vs. AIQ: 13.59 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.20
AIQ's PE(NRI) is ranked higher than
81% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. AIQ: 20.20 )
Ranked among companies with meaningful PE(NRI) only.
AIQ' s 10-Year PE(NRI) Range
Min: 10.08  Med: 23.69 Max: 781.25
Current: 20.2
10.08
781.25
P/S 0.45
AIQ's P/S is ranked higher than
95% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. AIQ: 0.45 )
Ranked among companies with meaningful P/S only.
AIQ' s 10-Year P/S Range
Min: 0.08  Med: 0.65 Max: 1.54
Current: 0.45
0.08
1.54
PFCF 3.34
AIQ's PFCF is ranked higher than
97% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.01 vs. AIQ: 3.34 )
Ranked among companies with meaningful PFCF only.
AIQ' s 10-Year PFCF Range
Min: 0.74  Med: 5.51 Max: 28.19
Current: 3.34
0.74
28.19
POCF 1.94
AIQ's POCF is ranked higher than
97% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.04 vs. AIQ: 1.94 )
Ranked among companies with meaningful POCF only.
AIQ' s 10-Year POCF Range
Min: 0.44  Med: 2.59 Max: 5.51
Current: 1.94
0.44
5.51
EV-to-EBIT 14.78
AIQ's EV-to-EBIT is ranked higher than
78% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.19 vs. AIQ: 14.78 )
Ranked among companies with meaningful EV-to-EBIT only.
AIQ' s 10-Year EV-to-EBIT Range
Min: -40.5  Med: 12.90 Max: 80.2
Current: 14.78
-40.5
80.2
Current Ratio 1.58
AIQ's Current Ratio is ranked lower than
78% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. AIQ: 1.58 )
Ranked among companies with meaningful Current Ratio only.
AIQ' s 10-Year Current Ratio Range
Min: 1  Med: 1.59 Max: 2.87
Current: 1.58
1
2.87
Quick Ratio 1.58
AIQ's Quick Ratio is ranked lower than
67% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. AIQ: 1.58 )
Ranked among companies with meaningful Quick Ratio only.
AIQ' s 10-Year Quick Ratio Range
Min: 1  Med: 1.59 Max: 2.87
Current: 1.58
1
2.87
Days Sales Outstanding 53.51
AIQ's Days Sales Outstanding is ranked higher than
66% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. AIQ: 53.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
AIQ' s 10-Year Days Sales Outstanding Range
Min: 39.79  Med: 48.08 Max: 59.52
Current: 53.51
39.79
59.52

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.63
AIQ's Price/Projected FCF is ranked higher than
95% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. AIQ: 0.63 )
Ranked among companies with meaningful Price/Projected FCF only.
AIQ' s 10-Year Price/Projected FCF Range
Min: 0.17  Med: 0.80 Max: 3.78
Current: 0.63
0.17
3.78
Price/Median PS Value 0.69
AIQ's Price/Median PS Value is ranked higher than
77% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. AIQ: 0.69 )
Ranked among companies with meaningful Price/Median PS Value only.
AIQ' s 10-Year Price/Median PS Value Range
Min: 0.17  Med: 1.00 Max: 3.25
Current: 0.69
0.17
3.25
Earnings Yield (Greenblatt) (%) 6.96
AIQ's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. AIQ: 6.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AIQ' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.2  Med: 7.10 Max: 11
Current: 6.96
1.2
11
Forward Rate of Return (Yacktman) (%) 20.30
AIQ's Forward Rate of Return (Yacktman) (%) is ranked higher than
80% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.17 vs. AIQ: 20.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AIQ' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 5  Med: 18.40 Max: 148.5
Current: 20.3
5
148.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AI6M.Germany,
Alliance HealthCare Services Inc Its diagnostic imaging services include magnetic resonance imaging technology and positron emission tomography/computed tomography services that generate representations of the internal anatomy and convert them to film or digital media. The Company operates in two reportable segments, Imaging and Radiation Oncology. It offers non scan-based services, which comprise the use of imaging systems under a short-term contract. In addition, it provides radiation oncology services that include conventional beam therapy, 3-D conformal radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, stereotactic radiosurgery, low dose rate brachytherapy, and high dose rate brachytherapy for the treatment of cancer; and stereotactic radiation oncology services. Further, the Company offers ancillary services, such as marketing support, education, training, and billing assistance. It provides imaging and therapeutic services through hospitals and clinics, independent imaging and radiation oncology centers, and other healthcare providers on a shared-service and full-time service basis, as well as provides services through fixed-sites, primarily to hospitals or health systems. It competes with RadNet, Inc., Center for Diagnostic Imaging. The Company is subject to federal and state government regulations. It is also subject to various environmental, health, and safety laws regulated by the government.
» More Articles for AIQ

Headlines

Articles On GuruFocus.com
comment on AIQ Aug 20 2011 
Alliance Imaging Inc. Reports Operating Results (10-K) Mar 14 2011 
Alliance Imaging Inc. Reports Operating Results (10-Q) Nov 05 2010 
Alliance Imaging Inc. (AIQ) CEO Paul S Viviano buys 10,000 Shares Aug 09 2010 
Alliance Imaging Announces Acquisition of Shared P.E.T. Imaging, LLC Dec 16 2008 
Alliance Imaging Schedules Conference Call and Webcast to Review Full Year 2009 Financial Guidance Dec 12 2008 

More From Other Websites
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 23 2015
Alliance HealthCare Services Announces Funding for Incremental Term Loan Jun 22 2015
Alliance HealthCare Services Announces Funding for Incremental Term Loan Jun 22 2015
Alliance HealthCare Services Receives Multiple Avatar Patient Experience & Satisfaction Awards for... Jun 17 2015
Alliance Oncology Exhibits Poster Presentation at American College of Radiation Oncology Annual... Jun 17 2015
Alliance Oncology Exhibits Poster Presentation at American College of Radiation Oncology Annual... Jun 17 2015
Alliance HealthCare Services and Dignity Health Bay Area Bring CyberKnife® Cancer Treatment to... Jun 16 2015
Alliance HealthCare Services and Dignity Health Bay Area Bring CyberKnife® Cancer Treatment to... Jun 16 2015
Alliance Healthcare Services, Inc. -- Moody's affirms Alliance's B1 CFR; outlook changed to stable... Jun 09 2015
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 08 2015
Philadelphia CyberKnife Exhibits Three Poster Presentations at American College of Radiation... Jun 04 2015
Philadelphia CyberKnife Exhibits Three Poster Presentations at American College of Radiation... Jun 04 2015
Luther W. Brady, M.D. Awarded George Washington University President’s Medal May 26 2015
ALLIANCE HEALTHCARE SERVICES, INC Financials May 19 2015
10-Q for Alliance HealthCare Services, Inc. May 14 2015
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 10-Q, Quarterly Report May 11 2015
Alliance HealthCare posts 1Q profit May 07 2015
Alliance HealthCare posts 1Q profit May 07 2015
Alliance HealthCare Services Inc Earnings Call scheduled for 5:00 pm ET today May 07 2015
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK